Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Viriom","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viriom Initiates Phase 2 Clinical Study of Elsulfavirine for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Viriom","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viriom Initiates Phase 2 Study Investigating Efficacy of Intramuscular Long-Acting Injectable Nanoformulation of VM1500A in HIV Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Viriom","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viriom and Chromis Publish Results of a Post-Marketing Clinical Study in 940 COVID-19 Patients Confirming Efficacy of Avifavir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Viriom

    Menu

    Viriom

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Viriom

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Viriom and Chromis Publish Results of a Post-Marketing Clinical Study in 940 COVID-19 Patients Confirming Efficacy of Avifavir

              Details:

              The efficacy and safety of Avifavir was statistically significantly demonstrated in two Phase 2 and Phase 3 clinical trials in 460 medium severe and severely ill COVID-19 patients conducted between April and October 2020.

              Lead Product(s): Favipiravir

              Therapeutic Area: Infections and Infectious Diseases Product Name: Avifavir

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Russian Direct Investment Fund

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Viriom

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Viriom Initiates Phase 2 Study Investigating Efficacy of Intramuscular Long-Acting Injectable Nanoformulation of VM1500A in HIV Patients

              Details:

              Phase 2a study aims to select a therapeutic dose and assess safety and efficacy of VM-1500A-LAI multiple injections in HIV+ virally suppressed patients vs a marketed Elpida®-based once-daily regimen.

              Lead Product(s): VM1500A

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 04, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Viriom

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Viriom Initiates Phase 2 Clinical Study of Elsulfavirine for Treatment of COVID-19

              Details:

              Phase 2 clinical study expands the ongoing research into elsulfavirine, which includes confirmation of elsulfavirine antiviral activity against COVID-19 infection by Zhejiang University in China.

              Lead Product(s): Elsulfavirine,Favipiravir

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY